Gwinner,
IMO, the advancement of bird flu situation and positive results have clouded the picture of WHEN a license, development agreement /JV, buyout situation might occur. As to communication, doesn't seem to matter who CEO is ... communication has always been the absolute worst. Taking advantage of social media ..... laughable here quite honestly.
There are sooooo many things I'd like to say here but it wouldn't really matter.
Bottomline with each passing day I'm more and more leaning towards Payne needing to explore the sale of the company.
We all know the algae strain works. Been tested ad nauseum over multiple verticals. ZIVO has identified the key molecule ... knows the mechanism of action ...... has developed the GRAS version and mass production techniques for large scale nutraceutical/ingredient possibilities. They know the key is regulation/modulation of the bodies inflammation response which is the underlying cause of NUMEROUS conditions in both human and animal health.
With the eyes of multiple pharmas are apparently on it ..... IMO .... it is time for a buyout. Payne should ask for offers .... get on offer out in the marketplace ..... say no .... and let the auction begin. I don't see a long term plan for the company. No succession plan. Can't spend years figuring out the next vertical to work on. Time to put this in the hands of a company that can do something with it.
I still stick with my opinion this is a $50 stock minimum with a coccidiosis license but if no one is looking who gonna care ? With Bird Flu. Hell that is a wild card that could bring massive attention and amounts of money. I don't know what that's worth but ... more than $50. All the potential verticals .... I've already said this thing is worth more than $1 billion .... but I don't see a plan to make that happen.
Amigo Mike
Market Data 
Markets 
